Online inquiry

IVTScrip™ mRNA-Human AGAP2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK8988MR)

This product GTTS-WK8988MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the AGAP2 protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001122772.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 116986
UniProt ID Q99490
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human AGAP2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK8988MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK18021MR IVTScrip™ mRNA-Human AHI1, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AHI1
GTTS-WK17628MR IVTScrip™ mRNA-Human ANKRD46, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANKRD46
GTTS-WK22099MR IVTScrip™ mRNA-Human ASB7, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASB7
GTTS-WK21991MR IVTScrip™ mRNA-Human ARHGAP26, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP26
GTTS-WK7575MR IVTScrip™ mRNA-Human ABI3, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABI3
GTTS-WK21981MR IVTScrip™ mRNA-Human ARHGAP10, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP10
GTTS-WK16704MR IVTScrip™ mRNA-Human ANKRD18A, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANKRD18A
GTTS-WK4078MR IVTScrip™ mRNA-Human WNT4, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA WNT4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW